A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Activity of KH801 Injection in Patients With Advanced Solid Tumors
Latest Information Update: 21 Oct 2024
At a glance
- Drugs KH 801 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Chengdu Kanghong Pharmaceutical
Most Recent Events
- 07 Aug 2024 Last checked against the ClinicalTrials.gov record.
- 23 Apr 2024 New trial record